SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Syndax Pharmaceuticals Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$13.09+0.19 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- –
- Dividend yield
- –
Syndax Pharmaceuticals Inc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Net product revenue | $124.84M | $7.68M | $0 | $0 | 72.4% | +1525.6% |
| Collaboration revenue | $42.37M | $0 | $0 | – | 24.6% | – |
| Milestone revenue | $5.14M | $16.00M | $0 | $0 | 3.0% | -67.9% |
By region
From the segment and revenue-disaggregation notes of Syndax Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.